Pharmacological Treatment of the Psychosis of Alzheimer’s Disease (original) (raw)
Finkel SI, Costa e Silva J, Cohen GD, et al. Behavioral and psychological symptoms of dementia: a consensus statement on current knowledge and implication for research and treatment. Am J Geriatr Psychiatry 1998; 6: 97–100 Google Scholar
Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl.: 9–15 PubMed Google Scholar
Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry 1989; 146: 577–87 PubMedCAS Google Scholar
Drevets WC, Rubin EG. Psychotic symptoms and the longitudinal course of senile dementia of Alzheimer’s type. Biol Psychiatry 1989; 25: 39–48 ArticlePubMedCAS Google Scholar
Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer’s disease. Biol Psychiatry 1991; 29(3): 224–32 ArticlePubMedCAS Google Scholar
US Food and Drug Administration. FDA public advisory: deaths with antipsychotics in elderly patients with behavioral disturbances [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm [Accessed 2005 Apr 13]
Jeste D, Finkel S. Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8: 29–34 ArticlePubMedCAS Google Scholar
Feldman H, Gathier S, Hecker J, et al. A 24 week randomized, double-blind study of donepezil in moderate to severe lzheimer’s disease. Neurology 2001; 57: 613–20 ArticlePubMedCAS Google Scholar
Ballard C, Margallo-Lana M, Juszczak C, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomized double blind placebo controlled trial. BMJ 2005; 330: 874–7 ArticlePubMedCAS Google Scholar
Tariot PN, Solomon PR, Morris JC, et al. A 5 month, randomized placebo controlled trial of galantamine in Alzheimer’s disease. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–76 CAS Google Scholar
Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. CNS Spectr 2005; 10(11 Suppl. 18): 22–5 PubMed Google Scholar
Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–9 ArticlePubMedCAS Google Scholar
Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer’s disease: a meta nalysis. JAMA 2003; 289: 210–6 ArticlePubMedCAS Google Scholar
Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioral symptoms in Alzheimer’s disease patients: an analysis f neuropsychiatric inventory data of two randomized, controlled studies. Int J Geriatr Psychiatry 2005; 20: 459–64 ArticlePubMedCAS Google Scholar
Schneider LS, Pollack VE, Lyness SA. A meta analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63 PubMedCAS Google Scholar
Lanctot KI, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59(10): 550–61 ArticlePubMedCAS Google Scholar
Madhusoodanan S. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric patients. Am J Geriatr Psychiatry 2001; 9(3): 283–8 PubMedCAS Google Scholar
Rovner BW, Edelman BA, Cox MP, et al. The impact of antipsychotic drug regulations on psychotropic prescribing practices in nursing homes. Am J Psychiatry 1992; 149(10): 1390–2 PubMedCAS Google Scholar
Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12(2): 135–50 Article Google Scholar
Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatrie symptoms of dementia: a review of the evidence. AMA 2005; 293(5): 596–8 ArticleCAS Google Scholar
Stone M. Deaths in controlled trials of atypical antipsychotics in patients with behavioral disturbances from dementia. 45th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting; 2005 Jun 6–9; Boca Raton (FL)
Schneider LS, Dagerman KS, Insel P. Risk of deaths with atypical antipsychotic treatment for dementia: meta analysis of randomized placebo controlled trials. JAMA 2005; 294(15): 1934–43 ArticlePubMedCAS Google Scholar
Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression,agitation and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–43 ArticlePubMedCAS Google Scholar
Cavazzoni P, Young CA, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. 44th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting; 2004 Jun 1–4; Phoenix (AZ)
Deberdt WG, Dysken MD, Rappaport SR, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 3(8): 722–30 Google Scholar
Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. J Clin Psychiatry 1999; 60: 107–15 ArticlePubMedCAS Google Scholar
De Dyne PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms f dementia. Neurology 1999; 53: 946–55 Article Google Scholar
Greenspan A, Eerdekens M, Mahmoud R. Is there an increased rate of cerebrovascular events among dementia patients [poster]. 24th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); 2004 Jun 20–24; Paris
Nelson JC. Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what’s a clinician to do? J Clin Psychiatry 2005; 66(8): 1071 ArticlePubMed Google Scholar
Hermann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113–5 Article Google Scholar
American Diabetic Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the study of obesity consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetic Care 2004; 27: 596–601 Article Google Scholar
Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids, in olanzapine treated patients with schizophrenia or related psychosis. J Clin Psychiatry 2000; 61: 742–9 ArticlePubMedCAS Google Scholar
Wirsching DA, Spelling BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83 Article Google Scholar
Newcomer JW. Atypical-associated changes in glucose regulation in schizophrenia may occur independently of changes in adiposity. Acapulco: American College of Neuropsychopharmacology, 1999 Google Scholar
Ershefsky L. Pharmacological profile of risperidone. Can J Psychiatry 1993; 38Suppl. 3: 580–8 Google Scholar
Chauloff F, Laude D, Baudrie V. Effects of 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol 1990; 187: 435–43 Article Google Scholar
Gupta S, Steinmeyer C, Frank B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Therapeutics 2003; 10(5): 348–55 Article Google Scholar
Meatherall R, Younes J. Fatality from olanzapine induced hyperglycemia. J Forensic Sciences 2002; 47: 893–6 Google Scholar
Torrey EF, Swalwell C. Fatal olanzapine induced ketoacidosis. Am J Psychiatry 2003; 160: 2241 ArticlePubMed Google Scholar
Geodon® (ziprasidone) [prescribing information]. New York: Pfizer, Inc., 2005 May
Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series: treatment of dementia and its behavioral disturbances. Postgrad Med Special Report 2005: 1-108
Jeste DV, Olamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157(7): 1150–5 ArticlePubMedCAS Google Scholar
Chan WC, Lam LC, Chay CN, et al. A double-blind randomized comparison of risperidone and haloperidol in the treatment of behavioral and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001; 16: 1156–62 ArticlePubMedCAS Google Scholar
Rabinowitz J, Katz IR, De Deyn PP, et al. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry 2004; 65(10): 1329–34 ArticlePubMedCAS Google Scholar
Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatri Soc 1999; 47: 716–9 CAS Google Scholar
Edell WS, Rupnow MRT. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer’s disease. Managed Care Interface 2003; 16(5): 64–7 PubMed Google Scholar
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer’s disease in nursing care facilities: a randomized, double blind placebo controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968–76 ArticleCAS Google Scholar
De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19: 115–26 ArticlePubMed Google Scholar
Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: a double blind, randomized study in acutely agitated patients ith dementia. Neuropsychopharmacology 2002; 26: 494–504 ArticlePubMedCAS Google Scholar
Verhey FRJ, Verkaack M, Lousberg R. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dement Geriatr Cogn Disord 2006; 21: 1–8 ArticlePubMedCAS Google Scholar
Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; (2): CD002852
PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14(9): 767–76 Article Google Scholar
Zhong K, Tariot P, Minkwitz M, et al. Quetipine for treatment of agitation in elderly institutionalized patients with dementia: a randomized double blind trial. American College of Neuropsychopharmacology Annual Meeting; 2004 Dec 12–16; San Juan
De Deyn P, Jeste DV, Auby P, et al. Aripiprazole in dementia of Alzheimer’s type [poster]. 16th Annual Meeting of American Association for Geriatric Psychiatry; 2003 Mar 1–4; Honolulu (HI)
Streim J, Breder C, Swanink R, et al. Flexible dose aripiprazole in psychosis of Alzheimer’s dementia [poster]. 157th American Association Meeting; 2004 May 1–6; New York (NY)
Breder C, Swanink R, Marcus R, et al. Dose ranging study of aripiprazole in patients with Alzheimer’s dementia [poster]. 157th American Association Meeting; 2004 May 1–6; New York (NY)
Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271–84 ArticlePubMedCAS Google Scholar
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo controlled trials. Am J Geriatr Psychiatry 2006; 14(3): 191–210 PubMed Google Scholar
The Parkinson Study Group. Low dose clozapine for the treatment of drug induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757–63 Article Google Scholar
Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson’s disease psychosis: 5 year follow up review. Clin Neuropharmacol 2003; 26(1): 8–11 ArticlePubMedCAS Google Scholar
Kozman C, Engelhart L, Long S, et al. No evidence for relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. In: Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York (NY)
Porsteinsson AP, Tariot PN, Erb R, et al. Placebo controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9(1): 58–66 PubMedCAS Google Scholar
Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open label extension of double blind trial. Am J Geriatr Psychiatry 2003; 11: 434–40 PubMed Google Scholar
Tariot PN, Raman R, Jakinovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer’s disease complicated by agitation. Am J Geriatr Psychiatry 2005; 13(11): 942–9 PubMed Google Scholar
Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54–61 PubMedCAS Google Scholar
Olen JT, Fox LS, Pawluezyk S, et al. A pilot randomized trial of carbamazepine for behavior symptoms in treatment-resistant outpatients with Alzheimer’s disease. Am J Geriatr Psychiatry 2001; 9: 400–5 Google Scholar
Blesa R. Noncognitive symptoms and long term treatment expectations for Alzheimer’s disease. Alzheimer Dis Assoc Disord 2004; 18Suppl. 1: S9–16 ArticlePubMedCAS Google Scholar
Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214–9 ArticlePubMedCAS Google Scholar
Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD 2000): randomized double-blind trial. Lancet 2004; 363: 2105–15 ArticlePubMedCAS Google Scholar
Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzherimer’s disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–95 ArticlePubMedCAS Google Scholar
Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate to severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41 ArticlePubMedCAS Google Scholar
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease lready receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317–24 ArticlePubMedCAS Google Scholar
Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk for falls among community dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 2005; 60: 622–6 ArticlePubMed Google Scholar
Panneman MJ, Goettsch WG, Kramarz P, et al. The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. Drags Aging 2003; 20: 833–9 Article Google Scholar
Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159(3): 460–5 ArticlePubMed Google Scholar
Finkel SI, Mintzer JE, Dysken M, et al. A randomised placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 2004: 9–18 Article Google Scholar
Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591–3 PubMedCAS Google Scholar
Olafsson K, Jorgansen S, Jensen HV, et al. Fluoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 1992; 6: 453–6 Article Google Scholar
Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271–8 ArticlePubMedCAS Google Scholar
Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12–6 ArticlePubMedCAS Google Scholar
Katz IR. Risks and benefits of atypical antipsychotics in dementia: a balancing act. Long-Term Care Interface 2004; Nov: 51
Lantz MS. Atypical antipsychotics and dementia: dealing with an emerging risk profile. Psychiatric Rounds Clinical Geriatrics 2005; 13(4): 26–30 Google Scholar
Kelly PA, Carney EA. Managing dementia: risks of using versus not using atypical antipsychotics. Curr Psychiatry 2005; 4(8): 15–28 Google Scholar
American Association for Geriatric Psychiatry. Comment on the US Food and Drag Administration’s (FDA) Advisory on off-label use of atypical antipsychotics in the elderly [online]. Available from URL: http://www.aagponline.org/prof/antipsychstat_0705.asp [Accessed 2005 Oct 31]
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drags in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38 ArticlePubMedCAS Google Scholar